Physician profile
Amber C Grantham
NPI 1235689217
$1,328.87
in general payments reported to CMS, 2019-2025
19 companies · $514 in 2025
The $514 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.74 · 2022: $24.51 · 2023: $217 · 2024: $551 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,281.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $301.98 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $221.89 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Antares Pharma, INC. | $132.40 | 2024-2025 | Xyosted |
| Abbvie INC. | $122.86 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $84.29 | 2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $78.66 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $55.56 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $46.42 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $44.15 | 2023-2024 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.35 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.20 | 2024-2025 | Jardiance |
| Halozyme INC | $30.04 | 2023 | |
| Dexcom, INC. | $27.78 | 2024-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $24.51 | 2022 | |
| Genentech USA, INC. | $22.74 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $19.48 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.14 | 2025 | |
| Amgen INC. | $15.63 | 2025 | Krystexxa |
| Janssen Pharmaceuticals, INC | $13.79 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Grantham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.